CONTACT US   |  (864) 397-5101

Elkem Celebrates Grand Opening of New Medical Grade Silicones Facility

Elkem opening

Elkem Silicones celebrated the grand opening of its new specialized facility for producing high purity medical silicones on Wednesday, September 28, in York, S.C.  Customers and local, state, and federal officials, attended the event which included a ribbon-cutting ceremony, facility tours and a reception.

Designed to produce high purity silicone materials that meet the MedTech and Pharma market requirements, this new 18,000 sq.ft. site features state-of-the-art ISO-certified Class 7 and Class 8 clean rooms.

Operations at this site are controlled under one quality management system that meets the requirements of ISO 9001, ISO 13485 and IPEC Good Manufacturing Practice (GMP) guidelines. 

“Elkem’s investment in this highly specialized facility demonstrates our commitment to growing with our customers around the world in medical implantable and pharmaceutical applications,” said Bertrand Mollet, president of Elkem Silicones Americas. “As the only fully integrated silicone supplier in this space, we are incredibly proud of this facility and all the opportunities it offers our customers.”

“Now, customers have a choice in their partner for quality medical grade silicones,” adds Bob Waitt, global strategic marketing director of Elkem’s Life Sciences.  “This is another example of Elkem’s commitment to raising the bar for what customers should come to expect of their silicone partner.  Whether addressing supply security risks or next generation device development, we now have a world class manufacturing infrastucture to combine with our comprehensive implant grade product range and global technical & regulatory support network to meet critical market needs. This is good news for our customers and, most importantly, patient care.”

Serving as Elkem’s global center of excellence for medical grade silicones, the company produces medical grade liquid silicone rubber (LSR), high consistency rubber (HCR), high purity silicone gels, silicone adhesives and dispersions marketed under the Silbione® Biomedical brand in this highly controlled environment in York.  Elkem’s Silbione® Biomedical products are supported by Master Access Files (MAF), and where applicable Drug Master Files (DMF), filed with the U.S. Food and Drug Administration (FDA).

Located on Timberland Court, this new facility is Elkem’s second operational facility in York.  In 2012, the company opened its main manufacturing campus for North America on Park Place Rd., which is located a half mile from the new facility.

For more information about Elkem’s full range of advanced silicone materials for medical, implantable and drug delivery applications, call (866) 474-6342 or visit

#    #    #

About Elkem Elkem is one of the world’s leading providers of advanced material solutions shaping a better and more sustainable future. The company develops silicones, silicon products and carbon solutions by combining natural raw materials, renewable energy and human ingenuity. Elkem helps its customers create and improve essential innovations like electric mobility, digital communications, health and personal care as well as smarter and more sustainable cities. With a strong track record since 1904, its global team of more than 7,000 people has a joint commitment to stakeholders: Delivering your potential. In 2022, Elkem obtained a Platinum score from EcoVadis, which rated the company among the world’s top 1% on sustainability transparency, and the company achieved an operating income of U.S. $3 billion. Elkem is listed on the Oslo Stock Exchange (ticker: ELK).

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.